Literature DB >> 10673683

Epstein-Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond-Blackfan anemia.

S Ohga1, Y Kanaya, H Maki, H Takada, K Ohshima, M Kanda, A Nomura, A Suminoe, A Matsuzaki, T Hara.   

Abstract

A 7-year-old boy with Diamond-Blackfan anemia (DBA) developed lymphoproliferative disease (LPD) after a cord blood transplant (CBT). 3.1 x 107/kg mononuclear cells from an HLA one-locus mismatched CB were transplanted after conditioning with total body irradiation (8 Gy), cyclophosphamide (200 mg/kg) and antithymocyte globulin (10 mg/kg). Complete engraftment occurred on day 33 post transplant. Despite the resolution of grade II graft-versus-host disease (GVHD), he died of lymphoma on day 130 post transplant. The tumor was of donor origin, indicating clonal proliferation of Epstein-Barr virus (EBV)-infected B cells. This is the first report of EBV-LPD after CBT. Post-transplant LPD can be a serious EBV-associated complication of CB grafts. Bone Marrow Transplantation (2000) 25, 209-212.

Entities:  

Mesh:

Year:  2000        PMID: 10673683     DOI: 10.1038/sj.bmt.1702138

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Epstein-Barr virus infection after unrelated cord blood transplantation: reactivation or reinfection?

Authors:  Keisei Kawa; Akihisa Sawada; Maho Koyama; Masami Inoue
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

2.  Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.

Authors:  Claudio G Brunstein; Daniel J Weisdorf; Todd DeFor; Juliet N Barker; Jakub Tolar; Jo-Anne H van Burik; John E Wagner
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

3.  Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia.

Authors:  Yoshinari Kawabata; Makoto Hirokawa; Yoshinobu Saitoh; Shigeki Kosugi; Tomoko Yoshioka; Masumi Fujishima; Naohito Fujishima; Yoshihiro Kameoka; Hirobumi Saitoh; Masaaki Kume; Naoto Takahashi; Ken-ichi Sawada
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

4.  Quantitative monitoring of circulating Epstein-Barr virus DNA for predicting the development of posttransplantation lymphoproliferative disease.

Authors:  S Ohga; E Kubo; A Nomura; H Takada; N Suga; E Ishii; A Suminoe; T Inamitsu; A Matsuzaki; N Kasuga; T Hara
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

5.  Successful unrelated cord blood transplantation for Epstein-Barr virus-associated lymphoproliferative disease with hemophagocytic syndrome.

Authors:  Taikai Toubo; Naohiro Suga; Shouichi Ohga; Akihiko Nomura; Yasuhiro Onoe; Hidetoshi Takada; Toshiro Hara
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

6.  Diamond-Blackfan anemia in Japan: clinical outcomes of prednisolone therapy and hematopoietic stem cell transplantation.

Authors:  Shouichi Ohga; Hideo Mugishima; Akira Ohara; Seiji Kojima; Kohji Fujisawa; Keiko Yagi; Masamune Higashigawa; Ichiro Tsukimoto
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

Review 7.  Posttransplant lymphoproliferative disease: pathogenesis, monitoring, and therapy.

Authors:  Richard F Ambinder
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

Review 8.  Human cord blood-derived viral pathogens as the potential threats to the hematopoietic stem cell transplantation safety: A mini review.

Authors:  Ali Noroozi-Aghideh; Maryam Kheirandish
Journal:  World J Stem Cells       Date:  2019-02-26       Impact factor: 5.326

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.